| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proteomics and Protein Markers |
1 Bio-Rad Laboratories, Marnes-La-Coquette, France.
2 CNRS UMR 5160, Montpellier, France.
3 I2T, Montpellier, France.
4 Hôpital Arnaud de Villeneuve, Montpellier, France.
5 Hôpital Lapeyronie, Département de Biochimie, Montpellier, France.
aAddress correspondence to this author at: CNRS UMR 5160, Faculté de Pharmacie, 15 avenue Charles Flahault, 34093 Montpellier Cedex 5, France. Fax 33-467-548-610; e-mail sylvie.villard{at}cpbs.univ-montp1.fr.
Background: B-Type natriuretic peptide (BNP1–32) as well as the N-terminal fragment of the prohormone containing residues 1–76 (NT-proBNP1–76), both cleavage products of the precursor proBNP1–108, are reported to be powerful markers for prognosis and risk stratification of heart failure. However, the intact precursor also circulates in the bloodstream. Assays for the detection of these cleavage products have been developed, but most of these assays may overestimate the concentrations of the cleavage products because they also measure the precursor form. It is therefore important to develop an immunoassay that specifically measures solely proBNP1–108 in plasma.
Methods: After carefully designing the peptide used to immunize mice, we selected a specific monoclonal antibody (mAb Hinge76) that recognizes the cleavage site of proBNP1–108, an epitope present only in the precursor form. mAb Hinge76 recognizes recombinant proBNP1–108 in a dose-dependent manner, without any significant cross-reactivity with either recombinant NT-proBNP1–76 or synthetic BNP1–32. By combining mAb Hinge76 with a polyclonal antibody directed against BNP1–32, we were able to set up a proBNP1–108-specific sandwich immunoassay able to confirm the presence of proBNP1–108 in blood samples.
Results: From a cohort of 50 healthy persons and 170 patients with congestive heart failure (CHF), our assay was able to differentiate healthy individuals from CHF patients (P <0.005). Interestingly, plasma proBNP1–108 concentrations were correlated with New York Heart Association classification. Moreover, a close relationship between proBNP1–108 and BNP1–32 concentrations may exist, as a good correlation (r2 = 0.89) was obtained when their respective concentrations were compared.
Conclusion: mAb Hinge76 is the first proBNP1–108-specific mAb produced that allows accurate estimation of proBNP1–108 concentrations in plasma.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  J. E. Rame, S. W. Tam, D. McNamara, M. Worcel, M. L. Sabolinski, A. H. Wu, and D. L. Dries Dysfunctional Corin I555(P568) Allele Is Associated With Impaired Brain Natriuretic Peptide Processing and Adverse Outcomes in Blacks With Systolic Heart Failure: Results From the Genetic Risk Assessment in Heart Failure Substudy Circ Heart Fail, November 1, 2009; 2(6): 541 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mair Clinical Significance of Pro-B-Type Natriuretic Peptide Glycosylation and Processing Clin. Chem., March 1, 2009; 55(3): 394 - 397. [Full Text] [PDF]
|
|
|
|
|
|
A. G. Semenov, A. B. Postnikov, N. N. Tamm, K. R. Seferian, N. S. Karpova, M. N. Bloshchitsyna, E. V. Koshkina, M. I. Krasnoselsky, D. V. Serebryanaya, and A. G. Katrukha Processing of Pro-Brain Natriuretic Peptide Is Suppressed by O-Glycosylation in the Region Close to the Cleavage Site Clin. Chem., March 1, 2009; 55(3): 489 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement Clin. Chem., November 1, 2008; 54(11): 1780 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Waldo, J. Beede, S. Isakson, S. Villard-Saussine, J. Fareh, P. Clopton, R. L. Fitzgerald, and A. S. Maisel Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1874 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hammerer-Lercher, B. Halfinger, B. Sarg, J. Mair, B. Puschendorf, A. Griesmacher, N. A. Guzman, and H. H. Lindner Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure Clin. Chem., May 1, 2008; 54(5): 858 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Luckenbill, R. H. Christenson, A. S. Jaffe, J. Mair, J. Ordonez-Llanos, F. Pagani, J. Tate, A. H. B. Wu, R. Ler, and F. S. Apple Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac Damage Clin. Chem., March 1, 2008; 54(3): 619 - 621. [Full Text] [PDF]
|
|
|
|
|
|
M. Nybo, M. Benn, R. Mogelvang, J. S. Jensen, P. Schnohr, J. F. Rehfeld, and J. P. Goetze Impact of Hemoglobin on Plasma Pro-B-Type Natriuretic Peptide Concentrations in the General Population Clin. Chem., November 1, 2007; 53(11): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. S. Apple, A. H.B. Wu, A. S. Jaffe, M. Panteghini, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, G. Francis, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure Circulation, July 31, 2007; 116(5): e95 - e98. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Miller, K. A. Hartman, M. F. Burritt, D. E. Grill, R. J. Rodeheffer, J. C. Burnett Jr, and A. S. Jaffe Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time Circulation, July 17, 2007; 116(3): 249 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Dries Relevance of Molecular Forms of Brain Natriuretic Peptide for Natriuretic Peptide Research Hypertension, May 1, 2007; 49(5): 971 - 973. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Heublein, B. K. Huntley, G. Boerrigter, A. Cataliotti, S. M. Sandberg, M. M. Redfield, and J. C. Burnett Jr Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide Hypertension, May 1, 2007; 49(5): 1114 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S.P. Lam, J. C. Burnett Jr, L. Costello-Boerrigter, R. J. Rodeheffer, and M. M. Redfield Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1193 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Liang, J. O'Rear, U. Schellenberger, L. Tai, M. Lasecki, G. F. Schreiner, F. S. Apple, A. S. Maisel, N. S. Pollitt, and A. A. Protter Evidence for Functional Heterogeneity of Circulating B-Type Natriuretic Peptide J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2575 - 2583. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
